Autosomal Clinical Trials in Barcelona
5 recruitingBarcelona, Spain
Showing 1–5 of 5 trials
Recruiting
Phase 3
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Autosomal Recessive Polycystic Kidney (ARPKD)
Otsuka Pharmaceutical Development & Commercialization, Inc.20 enrolled23 locationsNCT04782258
Recruiting
Phase 3
STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
Polycystic Kidney, Autosomal Dominant
University of Cologne420 enrolled30 locationsNCT07280585
Recruiting
Phase 2
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
Autosomal Dominant Polycystic Kidney Disease (ADPKD
Vertex Pharmaceuticals Incorporated24 enrolled43 locationsNCT07161037
Recruiting
Phase 2
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Autosomal Dominant Polycystic Kidney Disease
Calico Life Sciences LLC240 enrolled75 locationsNCT06902558
Recruiting
Phase 1
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
Pseudoxanthoma ElasticumEctonucleotide Pyrophosphatase/phosphodiesterase1 DeficiencyAutosomal Recessive Hypophosphatemic Rickets+2 more
Inozyme Pharma16 enrolled7 locationsNCT05734196